These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 31463577)
1. Evaluation of potential surrogate endpoints for prediction of overall survival in patients with castration-resistant prostate cancer: trial-level meta-analysis. Chen W; Li L; Ji S; Song X; Lu W; Zhou T Eur J Clin Pharmacol; 2019 Nov; 75(11):1521-1532. PubMed ID: 31463577 [TBL] [Abstract][Full Text] [Related]
2. Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer. Maeda H; Takeda K; Urushihara H; Kurokawa T Cancer Rep (Hoboken); 2021 Jun; 4(3):e1334. PubMed ID: 33455091 [TBL] [Abstract][Full Text] [Related]
4. Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients. Woo S; Suh CH; Wibmer AG; Becker AS; Teo MY; Gönen M; Hricak H; Scher HI; Morris MJ; Vargas HA Clin Genitourin Cancer; 2022 Feb; 20(1):69-79. PubMed ID: 34903480 [TBL] [Abstract][Full Text] [Related]
5. Longitudinal model-based meta-analysis for survival probabilities in patients with castration-resistant prostate cancer. Chen W; Li L; Ji S; Song X; Lu W; Zhou T Eur J Clin Pharmacol; 2020 Apr; 76(4):589-601. PubMed ID: 31925454 [TBL] [Abstract][Full Text] [Related]
6. Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial. Rathkopf DE; Beer TM; Loriot Y; Higano CS; Armstrong AJ; Sternberg CN; de Bono JS; Tombal B; Parli T; Bhattacharya S; Phung D; Krivoshik A; Scher HI; Morris MJ JAMA Oncol; 2018 May; 4(5):694-701. PubMed ID: 29522174 [TBL] [Abstract][Full Text] [Related]
7. Trial Level Analysis of Prostate-Specific Antigen-Related Versus Unrelated Endpoints in Phase III Trials of First-Line and Second-Line Medical Treatments of Patients With Metastatic Castration-Resistant Prostate Cancer. Colloca G; Vitucci P; Venturino A Clin Genitourin Cancer; 2016 Oct; 14(5):389-397. PubMed ID: 27108003 [TBL] [Abstract][Full Text] [Related]
8. Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials. Terrisse S; Karamouza E; Parker CC; Sartor AO; James ND; Pirrie S; Collette L; Tombal BF; Chahoud J; Smeland S; Erikstein B; Pignon JP; Fizazi K; Le Teuff G; JAMA Oncol; 2020 Feb; 6(2):206-216. PubMed ID: 31830233 [TBL] [Abstract][Full Text] [Related]
9. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review. Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777 [TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis. Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843 [TBL] [Abstract][Full Text] [Related]
11. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. Delanoy N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A; Thomson A; Krainer M; Guillot A; De Giorgi U; Hasbini A; Daugaard G; Bahl A; Chowdhury S; Caffo O; Beuzeboc P; Spaeth D; Eymard JC; Fléchon A; Alexandre J; Helissey C; Butt M; Priou F; Lechevallier É; Deville JL; Goupil MG; Morales R; Thiery-Vuillemin A; Gavrikova T; Barthelemy P; Sella A; Fizazi K; Baciarello G; Fererro JM; Laguerre B; Verret B; Hans S; Oudard S Eur Urol Oncol; 2018 Dec; 1(6):467-475. PubMed ID: 31158090 [TBL] [Abstract][Full Text] [Related]
12. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. Sonpavde G; Pond GR; Armstrong AJ; Galsky MD; Leopold L; Wood BA; Wang SL; Paolini J; Chen I; Chow-Maneval E; Mooney DJ; Lechuga M; Smith MR; Michaelson MD BJU Int; 2014 Dec; 114(6b):E25-E31. PubMed ID: 24298897 [TBL] [Abstract][Full Text] [Related]
14. The value of surrogate endpoints for predicting real-world survival across five cancer types. Shafrin J; Brookmeyer R; Peneva D; Park J; Zhang J; Figlin RA; Lakdawalla DN Curr Med Res Opin; 2016; 32(4):731-9. PubMed ID: 26743800 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis. Qin Z; Li X; Zhang J; Tang J; Han P; Xu Z; Yu Y; Yang C; Wang C; Xu T; Xu Z; Zou Q Medicine (Baltimore); 2016 Sep; 95(39):e4801. PubMed ID: 27684806 [TBL] [Abstract][Full Text] [Related]
16. Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer. McCool R; Fleetwood K; Glanville J; Arber M; Goodall H; Naidoo S Value Health; 2018 Oct; 21(10):1259-1268. PubMed ID: 30314628 [TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trials. Tunio M; Al Asiri M; Al Hadab A; Bayoumi Y Drug Des Devel Ther; 2015; 9():5291-9. PubMed ID: 26451085 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis. Miura N; Mori K; Mostafaei H; Quhal F; Sari Motlagh R; Abufaraj M; Pradere B; Aydh A; Laukhtina E; D'Andrea D; Saika T; Shariat SF Int J Clin Oncol; 2020 Nov; 25(11):1881-1891. PubMed ID: 32681382 [TBL] [Abstract][Full Text] [Related]
19. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291 [TBL] [Abstract][Full Text] [Related]
20. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer. Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]